DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval
05.12.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
Planegg/Munich, Germany, December 5, 2017
MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Canada
Janssen’s Tremfya(R) now approved in the U.S., Canada and the European Union
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Inc. (Janssen), previously reported Health Canada approval of Tremfya(R) (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Tremfya(R) (guselkumab) is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys’s proprietary HuCAL antibody library technology. MorphoSys is eligible to receive royalties on net sales of Tremfya(R).
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, said: “We are very pleased that Tremfya(R) has now been approved in three territories, namely the U.S., Canada and the European Union. We expect this drug will provide an important treatment option for patients living with moderate-to-severe plaque psoriasis.”
Beyond plaque psoriasis, Janssen is studying Tremfya(R) (guselkumab) in a Phase 3 psoriatic arthritis development program.
Further information about the Canadian approval of Tremfya(R) (guselkumab) can be found in a press release issued by Janssen on November 15, 2017.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Tremfya(R) is a registered trademark of Janssen Biotech, Inc.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Tel: +49 (0) 89 / 899 27-404
05.12.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 (0)89 899 27-0|
|Fax:||+49 (0)89 899 27-222|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|